Neurol. praxi. 2011;12(6):389-393

Immunosuppressive drugs in treating neurological diseases

MUDr.Jiří Pi»ha
Centrum Myasthenia gravis při Neurologické klinice 1. LF UK a VFN Praha

Immunosuppressive drugs have been used in the practice for more than fifty years. In treating neurological autoimmune diseases, their

role is irreplaceable. Azathioprine, cyclophosphamide, methotrexate, mycophenolate mofetil, mitoxantrone, cyclosporin A and tacrolimus

have been particularly used; clinical trials with cladribine and teriflunomide are under way. The paper deals with the mechanism

of action, adverse events and therapeutic regimens of individual agents; also covered are the indications of immunosuppressive drugs

in the most common autoimmune diseases. During treatment, it is always necessary to weigh the benefits against risks, monitor the

patient carefully and prevent adverse events.

polymyositis, myasthenia gravis.

Keywords: immunosuppressive drugs, multiple sclerosis, neuromyelitis optica, inflammatory polyneuropathies, dermatomyositis,

Published: December 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pi»ha J. Immunosuppressive drugs in treating neurological diseases. Neurol. praxi. 2011;12(6):389-393.
Download citation

References

  1. Claussen MC, Korn T. Immune mechanisms of new therapeutic strategies in MS - Teriflunomide. Clin Immunol. 2011; 139(1): 121-128. Go to original source...
  2. Distad BJ, Amato AA, Weiss MD. Inflammatory myopathies. Curr Treat Options Neurol. 2011; 13(2): 119-130. Go to original source... Go to PubMed...
  3. Dostál C, Pavelka K, Saudek F, Suchopar J, Ettler K. Cyclosporinum. Remedia 2005; 15: 33-52.
  4. Kieseier BC, Jeffery DR. Ther Adv Neurol Disord, 2010; 3(5) 277-291. Go to original source... Go to PubMed...
  5. Kovářová I. Léčba progresivní roztrouąené sklerózy. Neurol. praxi, 2008; 9(4): 223-225.
  6. Sathasivan S. Steroid and immunosuppressant drugs in myasthenia gravis, Nat Clin Pract Neurol, 2008; 4: 317-327. Go to original source... Go to PubMed...
  7. Sellner J, Boggild, Clanet MR, Hintzen Q, Illes Z, Montalba X, Du Pasquier RA, Polman CH, Sorensen PS, Hemmer B. EFNS guidelines on diagnosis and management of neuromyelitis optica. Europ J of Neurol 2010; 17: 1019-1032. Go to original source... Go to PubMed...
  8. Skeie GO, Apostolski S, Evoli A, Gilhus NE, Illae I, Harmsf L, Hilton-Jonesg D, Melms A, Verschuuren J, Horge HW. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Europ J of Neurol 2010; 17: 893-902. Go to original source... Go to PubMed...
  9. SÚKL, SPC, dostupné z http://www.sukl.cz/.
  10. Vachová M. Éra nových léků v terapii roztrouąené sklerózy. Neurol. praxi 2009; 10(5): 305-309.
  11. van Schaik IN, Eftimov F. Chronic Inflammatory Demyelinating Polyradiculoneuropathy - An Overview of Existing Treatment Options and Prospects for the Future. Europ Neurol Rev, 2011; 6(1): 45-51. Go to original source...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.